



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
John M. Covert  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim  
Jeffrey T. Helvey  
Eldora L. Ellison

Donald R. Banowitz  
Peter A. Jackman  
Brian J. Del Buono  
Mark Fox Evens  
Vincent L. Capuano  
Elizabeth J. Haanes  
Michael D. Specht  
Kevin W. McCabe  
Glenn J. Perry  
Edward W. Yee  
Grant E. Reed  
Virgil Lee Beaston  
Theodore A. Wood  
Joseph S. Ostroff  
Jason D. Eisenberg  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis

Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Laura A. Vogel  
Bashir M.S. Ali  
Shannon A. Carroll  
Anbar F. Khal  
Michelle K. Holoubek  
Marsha A. Rose  
Scott A. Schaller  
Lei Zhou  
W. Blake Coblenz  
James J. Pohl  
John T. Haran  
Mark W. Rygiel

Michael R. Malek\*  
Carla Ji-Eun Kim  
Doyle A. Siever\*  
Ulrike Winkler Jenks  
Paul A. Calvo  
Robert A. Schwartzman  
C. Matthew Rozier\*  
Shameek Ghose  
Randall K. Baldwin  
Daniel J. Nevriy

Registered Patent Agents•  
Karen R. Markowicz  
Matthew J. Dowd  
Mita Mukherjee  
Scott M. Woodhouse  
Peter A. Socarras  
Jeffrey K. Mills

Danielle L. Letting  
Lori Brandes  
Steven C. Oppenheimer  
Aaron S. Lukas  
Gaurav Asthana  
Robert E. Bakin  
Salvador M. Bezos

Of Counsel  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie  
Christopher P. Wrist

\* Admitted only in Maryland  
\* Admitted only in Virginia  
• Practice Limited to Federal Agencies

February 14, 2008

**WRITER'S DIRECT NUMBER:**  
(202) 772-8560

**INTERNET ADDRESS:**  
RESMOND@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

***Mail Stop Certificate of Correction Branch***

Re: U.S. Utility Patent No. 7,151,092 B2  
Issue Date: December 19, 2006  
(from Appl. No. 10/698,928; Filed: October 31, 2003)  
For: **Cytarabine Monophosphate Prodrugs**  
Inventors: Boyer *et al.*  
Our Ref: 2358.0180002/RWE/BAH

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Payment in the amount of **\$100.00** to cover the filing of a Certificate of Correction (37 C.F.R. § 1.20(a) is included with this submission and is being paid via online credit card payment;
2. Request for Corrected Certificate of Correction Under 37 C.F.R. § 1.322 and 1.323; and
3. Two (2) pages of Form PTO/SB/44.

The above-listed documents are filed electronically through EFS-Web.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
February 14, 2008  
Page 2

Fee payment is provided through online credit card payment. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Robert W. Esmond". The signature is fluid and cursive, with the first name "Robert" and last name "Esmond" clearly distinguishable.

Robert W. Esmond  
Attorney for Patentees  
Registration No. 32,893

RWE/MFG/dac  
Enclosures

667283\_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

BOYER *et al.*

Patent. No.: 7,151,092 B2

Issued: December 19, 2006

For: **Cytarabine**  
**Monophosphate Prodrugs**

Confirmation No.: 2990

Art Unit: 1626

Examiner: SOLOLA, T.

Atty. Docket: 2358.0180002/RWE/BAH

**Request for Certificate of Correction**  
**Under 37 C.F.R. § 1.322 and 1.323**


*Attn: Certificate of Correction Branch*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

It is hereby requested that a Certificate of Correction under 37 C.F.R. §§ 1.322 and 1.323 be issued for the above-captioned United States Patent. This Certificate of Correction is being requested due to mistakes which appear in the printed patent. These mistakes were made by both the U.S. Patent and Trademark Office and by Applicants. The mistakes made by Applicants are of a clerical or typographical nature, or of a minor character. Patentee(s) submit that correction of these errors does not introduce new matter.

Specifically, the printed patent contains the following errors for which a Certificate of Correction is respectfully requested:

Requested Change	Location of Support in File History	PTO or Applicant Error
In claim 4, column 60, line 2, please delete "carcinoma," and insert therein -- carcinoma.--	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 5, claim 25.	PTO Error
In claim 4, column 60, lines 5 to 15, please delete  	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 5, claim 25.	PTO Error
In claim 4, column 60, line 18, please delete "or a pharmaceutically acceptable salt thereof."	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 5, claim 25.	PTO Error
In claim 7, column 60, line 61, please delete "meiphalan" and insert therein -- melphalan --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 7, line 3.	PTO Error
In claim 7, column 60, line 62, please delete "chiorambucil" and insert therein -- chlorambucil --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 7, line 4.	PTO Error
In claim 7, column 60, line 62, please delete "duanbrubicin" and insert therein -- daunorubicin --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 7, line 4, and Application as filed, page 21, line 26.	Applicant Error
In claim 7, column 60, line 63, please delete "vairubicin" and insert therein -- valrubicin --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 7, line 5.	PTO Error
In claim 7, column 60, line 64, please delete "mercaptopuime" and insert therein -- mercaptopurine --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 7, line 8.	PTO Error
In claim 11, column 62, line 12, please delete "chiorambucil" and insert therein -- chlorambucil --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 8, line 8 from the bottom.	PTO Error

In claim 11, column 62, line 13, please delete "duanorubicin" and insert therein -- daunorubicin --.	Amendment and Reply Under 37 C.F.R. §1.114 filed on June 13, 2006, at page 8, line 7 from the bottom, and Application as filed, page 21, line 26	Applicant Error
--	--	-----------------

### ***Remarks***


The above-noted corrections do not involve such changes in the patent as would constitute new matter or would require reexamination.

A completed Form PTO/SB/44 accompanies this request, with the above-noted corrections printed thereon. Accordingly, a Certificate of Correction is believed proper and issuance thereof is respectfully requested.

This request is accompanied by payment of the fee set forth in 37 C.F.R. § 1.20(a). Fee payment is provided in the attached Credit Card Payment Form (PTO-2038). The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Patentees  
Registration No. 32,893

Date: Feb 14, 2007

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
648773\_2.DOC

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 1 of 2

PATENT NO: 7,151,092 B2


DATED: December 19, 2006

INVENTOR(S): BOYER *et al.*

It is certified that error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

In claim 4, column 60, line 2, please delete "carcinoma," and insert therein -- carcinoma.--

In claim 4, column 60, lines 5 to 15, please delete



In claim 4, column 60, line 18, please delete "or a pharmaceutically acceptable salt thereof."

In claim 7, column 60, line 61, please delete "meiphalan" and insert therein -- melphalan --.

In claim 7, column 60, line 62, please delete "chiorambucil" and insert therein -- chlorambucil --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW

Washington DC 20005-3934

Atty. Dkt. No. 2358.0180002/RWE/BAH

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 2 of 2

PATENT NO: 7,151,092 B2

DATED: December 19, 2006

INVENTOR(S): BOYER *et al.*

It is certified that error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

In claim 7, column 60, line 62, please delete "duanbrubicin" and insert therein -- daunorubicin --.

In claim 7, column 60, line 63, please delete "vairubicin" and insert therein -- valrubicin --.

In claim 7, column 60, line 64, please delete "mercaptopuime" and insert therein  
-- mercaptopurine --.

In claim 11, column 62, line 12, please delete "chiorambucil" and insert therein -- chlorambucil --.

In claim 11, column 62, line 13, please delete "duanorubicin" and insert therein -- daunorubicin --.

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

1100 New York Avenue, NW  
Washington DC 20005-3934

Atty. Dkt. No. 2358.0180002/RWE/BAH

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.